Header Logo

Michael Gold

Concepts (433)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Uterine Cervical Neoplasms
44
2023
297
5.220
Why?
Papillomavirus Infections
21
2020
143
2.900
Why?
Cervical Intraepithelial Neoplasia
25
2020
82
2.750
Why?
Colposcopy
23
2020
61
2.190
Why?
Endometrial Neoplasms
15
2024
189
2.160
Why?
Ovarian Neoplasms
15
2023
589
1.440
Why?
Papillomaviridae
15
2020
87
1.320
Why?
Antineoplastic Combined Chemotherapy Protocols
9
2024
409
1.250
Why?
Female
108
2024
15156
1.250
Why?
Mass Screening
6
2019
152
1.240
Why?
Adult
67
2024
7740
1.160
Why?
Middle Aged
63
2024
7138
1.130
Why?
Aged
54
2024
5400
1.090
Why?
Uterine Cervical Dysplasia
5
2016
35
1.010
Why?
Cervix Uteri
9
2017
65
1.000
Why?
Aged, 80 and over
33
2024
2021
0.980
Why?
Lymph Nodes
7
2023
103
0.970
Why?
Urokinase-Type Plasminogen Activator
3
2012
11
0.940
Why?
Humans
111
2024
28097
0.910
Why?
Fallopian Tube Neoplasms
5
2013
52
0.890
Why?
Genital Neoplasms, Female
8
2013
67
0.840
Why?
Peptide Fragments
3
2012
202
0.840
Why?
Neoplasm Recurrence, Local
9
2024
330
0.830
Why?
Neoplasm Staging
22
2021
478
0.750
Why?
Precancerous Conditions
7
2020
37
0.720
Why?
Carcinoma, Squamous Cell
9
2012
163
0.710
Why?
Positron Emission Tomography Computed Tomography
2
2017
31
0.680
Why?
Squamous Intraepithelial Lesions of the Cervix
1
2019
1
0.630
Why?
Vulvar Neoplasms
5
2012
25
0.620
Why?
Immunocompromised Host
1
2019
28
0.620
Why?
Retrospective Studies
28
2019
2546
0.620
Why?
Biopsy
10
2019
206
0.620
Why?
Community Health Services
1
2019
32
0.620
Why?
Adolescent
28
2021
3122
0.620
Why?
Peritoneal Neoplasms
4
2013
79
0.600
Why?
Early Detection of Cancer
8
2020
126
0.600
Why?
Disease Management
1
2019
88
0.590
Why?
Young Adult
21
2021
2733
0.570
Why?
Contraceptive Agents, Female
4
2010
9
0.540
Why?
Retroperitoneal Neoplasms
1
2017
9
0.540
Why?
Conization
2
2007
11
0.530
Why?
Vaginal Smears
9
2018
44
0.530
Why?
Carcinoma in Situ
2
2013
46
0.500
Why?
Sensitivity and Specificity
14
2018
521
0.480
Why?
Survival Rate
10
2012
430
0.480
Why?
Carboplatin
6
2024
111
0.450
Why?
Cystadenocarcinoma, Serous
2
2007
32
0.440
Why?
Uterine Neoplasms
5
2017
71
0.430
Why?
Fluorodeoxyglucose F18
4
2017
27
0.420
Why?
Antineoplastic Agents
6
2013
679
0.410
Why?
Adenocarcinoma
7
2018
298
0.410
Why?
Lymphatic Metastasis
9
2017
125
0.410
Why?
Radiopharmaceuticals
4
2017
71
0.410
Why?
Risk Assessment
7
2018
612
0.400
Why?
Disease-Free Survival
9
2012
237
0.400
Why?
United States
12
2020
2146
0.380
Why?
Neoplasms, Glandular and Epithelial
1
2012
72
0.370
Why?
Paclitaxel
5
2024
190
0.340
Why?
Prospective Studies
8
2018
1248
0.340
Why?
Positron-Emission Tomography
2
2008
99
0.340
Why?
Papanicolaou Test
6
2018
24
0.330
Why?
Lymph Node Excision
11
2023
100
0.330
Why?
Chemotherapy, Adjuvant
6
2009
113
0.320
Why?
Biomarkers, Tumor
8
2014
405
0.300
Why?
CA-125 Antigen
1
2008
19
0.300
Why?
Treatment Outcome
15
2013
2379
0.300
Why?
Genotype
10
2018
456
0.290
Why?
Contraceptives, Oral, Hormonal
2
1999
9
0.280
Why?
Electrocoagulation
1
2007
20
0.280
Why?
Human papillomavirus 16
5
2018
24
0.280
Why?
Sarcoma, Endometrial Stromal
1
2007
3
0.270
Why?
Contraception Behavior
2
1998
17
0.260
Why?
Vaginal Neoplasms
3
2016
12
0.260
Why?
Pregnancy
6
2019
1191
0.240
Why?
DNA, Viral
4
2014
56
0.240
Why?
Neoplasm Grading
6
2017
104
0.230
Why?
Amifostine
1
2003
5
0.210
Why?
Topotecan
1
2003
12
0.210
Why?
Pregnancy in Adolescence
2
2001
32
0.210
Why?
Patient Selection
2
2008
148
0.210
Why?
Cross-Sectional Studies
5
2019
961
0.210
Why?
Stress, Psychological
2
2010
221
0.210
Why?
Contraceptives, Postcoital
2
2001
2
0.210
Why?
Combined Modality Therapy
5
2013
300
0.210
Why?
Neutropenia
1
2003
41
0.210
Why?
Physician's Role
1
2003
29
0.200
Why?
Risk Factors
11
2013
2081
0.200
Why?
Sentinel Lymph Node Biopsy
3
2012
17
0.200
Why?
Cancer Survivors
1
2023
43
0.190
Why?
Double-Blind Method
5
2024
417
0.190
Why?
Radiography
5
2012
202
0.190
Why?
Clinical Trials as Topic
1
2003
214
0.190
Why?
Contraception
1
2001
22
0.190
Why?
Disease Progression
7
2013
473
0.180
Why?
Reproducibility of Results
4
2017
769
0.180
Why?
Job Satisfaction
1
2001
24
0.180
Why?
Estradiol
1
2001
175
0.170
Why?
Obesity
3
2020
669
0.170
Why?
Fellowships and Scholarships
1
2001
39
0.170
Why?
Papillomavirus Vaccines
3
2010
56
0.170
Why?
Radiotherapy, Adjuvant
4
2008
60
0.170
Why?
Gynecology
1
2001
58
0.170
Why?
Molecular Diagnostic Techniques
2
2012
21
0.170
Why?
Inservice Training
1
2000
9
0.170
Why?
Taxoids
2
2012
37
0.170
Why?
Neoplasms, Unknown Primary
1
1999
8
0.160
Why?
Physical Education and Training
1
2000
48
0.160
Why?
Medroxyprogesterone Acetate
3
2010
21
0.160
Why?
Medical Oncology
1
2001
94
0.160
Why?
Military Personnel
1
2000
47
0.160
Why?
Progestins
2
1999
11
0.160
Why?
Vibrio
1
2019
4
0.160
Why?
Clustered Regularly Interspaced Short Palindromic Repeats
1
2019
14
0.160
Why?
Physicians
1
2020
83
0.160
Why?
Adaptation, Psychological
1
2000
122
0.160
Why?
Attitude of Health Personnel
1
2020
143
0.150
Why?
Cytodiagnosis
1
2018
12
0.150
Why?
Genome, Bacterial
1
2019
70
0.150
Why?
CRISPR-Cas Systems
1
2019
48
0.150
Why?
Vagina
2
2016
42
0.150
Why?
Organoplatinum Compounds
2
2008
24
0.150
Why?
Electrosurgery
5
2012
15
0.150
Why?
Dose-Response Relationship, Drug
4
2008
607
0.150
Why?
Curettage
1
2017
4
0.140
Why?
Surveys and Questionnaires
6
2012
971
0.140
Why?
African Americans
1
2020
352
0.140
Why?
Students
1
2000
196
0.140
Why?
Practice Guidelines as Topic
1
2019
243
0.140
Why?
Amenorrhea
1
1997
5
0.140
Why?
Fallopian Tubes
1
1997
15
0.140
Why?
Predictive Value of Tests
3
2008
474
0.140
Why?
Injections, Subcutaneous
2
2008
60
0.140
Why?
Ovary
1
1997
69
0.130
Why?
Age Factors
5
2010
734
0.130
Why?
Oklahoma
7
2013
1007
0.130
Why?
Sexual Behavior
4
2012
91
0.130
Why?
Case Management
1
2016
11
0.130
Why?
Case-Control Studies
2
2008
722
0.130
Why?
Prognosis
3
2008
803
0.130
Why?
Specimen Handling
2
2013
33
0.130
Why?
Cohort Studies
6
2010
887
0.120
Why?
Laparoscopy
4
2002
146
0.120
Why?
Salvage Therapy
2
2007
34
0.120
Why?
Conversion Disorder
1
1995
2
0.120
Why?
Contraceptive Devices
1
1995
1
0.120
Why?
Levonorgestrel
1
1995
6
0.120
Why?
Health Knowledge, Attitudes, Practice
1
1998
297
0.120
Why?
Prevalence
3
2020
497
0.120
Why?
Personality Development
1
1994
6
0.120
Why?
Homosexuality, Female
1
1994
4
0.120
Why?
Homosexuality, Male
1
1994
17
0.110
Why?
Antibodies, Monoclonal, Humanized
3
2024
144
0.110
Why?
Microsatellite Instability
1
2014
10
0.110
Why?
Ki-67 Antigen
2
2012
23
0.110
Why?
Vulva
1
2013
5
0.110
Why?
Parenting
1
1994
56
0.110
Why?
Urine
1
2013
14
0.110
Why?
Bone Density
2
2010
100
0.110
Why?
Polyploidy
1
2013
12
0.110
Why?
Insurance, Health, Reimbursement
1
2013
10
0.100
Why?
Lymphocytes
1
2014
90
0.100
Why?
Genotyping Techniques
1
2012
21
0.100
Why?
Niacinamide
1
2013
31
0.100
Why?
Quality of Health Care
1
2013
80
0.100
Why?
Sterilization, Tubal
1
2012
6
0.100
Why?
Neoplasms, Squamous Cell
1
2012
5
0.100
Why?
Leiomyoma
1
2012
9
0.100
Why?
Protein-Tyrosine Kinases
1
2013
97
0.100
Why?
Cyclin-Dependent Kinase Inhibitor p16
1
2012
16
0.100
Why?
Placebos
2
2010
48
0.100
Why?
Menstruation
3
1998
9
0.100
Why?
Viral Load
1
2012
31
0.100
Why?
Hyaluronan Receptors
1
2012
31
0.100
Why?
Indoles
1
2013
99
0.100
Why?
Hysterectomy
4
2013
85
0.100
Why?
Genetic Heterogeneity
1
2012
31
0.090
Why?
Follow-Up Studies
6
2013
1013
0.090
Why?
Cisplatin
3
2007
179
0.090
Why?
Oncogene Proteins, Viral
3
2014
16
0.090
Why?
Protein Kinase Inhibitors
1
2013
156
0.090
Why?
Drug Administration Schedule
4
2009
224
0.090
Why?
Medical History Taking
1
2011
20
0.090
Why?
Methylphenidate
1
2010
8
0.090
Why?
Bone Diseases, Metabolic
1
2010
8
0.090
Why?
Pregnancy Complications, Neoplastic
1
2010
7
0.090
Why?
Central Nervous System Stimulants
1
2010
32
0.090
Why?
Retinoids
2
2001
38
0.090
Why?
Fatigue
1
2010
64
0.080
Why?
Vitamin D Deficiency
1
2010
31
0.080
Why?
Referral and Consultation
3
2014
97
0.080
Why?
Pregnancy Outcome
1
2010
131
0.080
Why?
Receptors, Urokinase Plasminogen Activator
1
2008
11
0.080
Why?
Pelvis
3
2023
38
0.080
Why?
Fibrin Tissue Adhesive
1
2008
5
0.070
Why?
Incidence
4
2012
562
0.070
Why?
Lymphedema
1
2008
15
0.070
Why?
Peritoneum
1
2008
8
0.070
Why?
Neoplasm Metastasis
1
2008
162
0.070
Why?
Contraceptives, Oral
2
2012
23
0.070
Why?
Receptors, Cell Surface
1
2008
114
0.070
Why?
Catheters, Indwelling
2
2007
19
0.070
Why?
Postmenopause
1
2008
83
0.070
Why?
Bridged-Ring Compounds
1
2007
18
0.070
Why?
Vesicovaginal Fistula
1
2007
4
0.070
Why?
Carcinoma, Adenosquamous
1
2007
12
0.070
Why?
Immunohistochemistry
3
2014
463
0.070
Why?
Image Processing, Computer-Assisted
1
2008
251
0.060
Why?
Pilot Projects
3
2014
433
0.060
Why?
Carcinosarcoma
1
2005
22
0.060
Why?
Preoperative Care
1
2006
81
0.060
Why?
Metabolism
2
1995
9
0.060
Why?
Male
5
2020
13491
0.060
Why?
Human papillomavirus 18
2
2018
6
0.060
Why?
Spectrometry, Fluorescence
1
2004
64
0.050
Why?
Cystadenocarcinoma, Papillary
1
2003
5
0.050
Why?
Amino Acid Sequence
1
2005
692
0.050
Why?
Ambulatory Care
1
2003
60
0.050
Why?
Molecular Sequence Data
1
2005
1054
0.050
Why?
Catheterization, Central Venous
1
2003
38
0.050
Why?
Clinical Trials, Phase II as Topic
1
2003
25
0.050
Why?
Multicenter Studies as Topic
1
2003
47
0.050
Why?
Antigens, Viral
1
2003
24
0.050
Why?
Gene Expression Profiling
1
2005
453
0.050
Why?
Neoplasm Invasiveness
2
2014
190
0.050
Why?
Thallium
1
2002
2
0.050
Why?
Whole-Body Counting
1
2002
3
0.050
Why?
Iridium Radioisotopes
1
2002
3
0.050
Why?
Abdomen
1
2002
41
0.050
Why?
ROC Curve
2
2013
144
0.050
Why?
Life Style
1
2023
89
0.050
Why?
DNA
1
2004
374
0.050
Why?
Lipectomy
1
2001
2
0.050
Why?
Pregnancy, Unwanted
1
2001
1
0.050
Why?
Gynecologic Surgical Procedures
1
2001
35
0.050
Why?
Uterine Cervical Diseases
2
2012
6
0.050
Why?
Thiourea
1
2001
17
0.050
Why?
Immunotherapy
1
2003
161
0.050
Why?
Age Distribution
2
2012
73
0.040
Why?
Benzoates
1
2001
30
0.040
Why?
B7-H1 Antigen
1
2021
38
0.040
Why?
Cytoreduction Surgical Procedures
1
2021
33
0.040
Why?
Diet
1
2023
232
0.040
Why?
Patient Education as Topic
1
2001
91
0.040
Why?
Mentors
1
2001
39
0.040
Why?
Neoadjuvant Therapy
1
2021
73
0.040
Why?
Bevacizumab
1
2021
103
0.040
Why?
Africa South of the Sahara
1
2020
13
0.040
Why?
Career Choice
1
2001
53
0.040
Why?
Carcinoma
1
2001
74
0.040
Why?
Wit and Humor as Topic
1
2000
2
0.040
Why?
Anthropology, Cultural
1
2000
4
0.040
Why?
Observation
1
2000
5
0.040
Why?
Education, Medical, Graduate
1
2001
108
0.040
Why?
Relaxation Therapy
1
2000
5
0.040
Why?
Military Medicine
1
2000
3
0.040
Why?
Health Care Surveys
1
2020
67
0.040
Why?
Receptors, Retinoic Acid
1
1999
32
0.040
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
1999
52
0.040
Why?
Fatal Outcome
1
1999
67
0.040
Why?
Contraindications
1
1999
13
0.040
Why?
Benzamides
1
1999
34
0.040
Why?
Logistic Models
2
2012
407
0.040
Why?
Self Concept
1
2000
53
0.040
Why?
Drug Prescriptions
1
1999
46
0.040
Why?
Gene Library
1
2019
45
0.040
Why?
Estrogens
1
1999
56
0.040
Why?
Chromosomes, Bacterial
1
2019
20
0.040
Why?
Social Support
1
2000
126
0.040
Why?
Culture Media
1
2019
99
0.040
Why?
Genetic Variation
1
2020
242
0.040
Why?
Gene Knockdown Techniques
1
2019
134
0.040
Why?
Longitudinal Studies
1
2000
414
0.040
Why?
Exercise
1
2023
479
0.040
Why?
Head and Neck Neoplasms
1
1999
87
0.040
Why?
Algorithms
2
2016
430
0.040
Why?
Brain Neoplasms
1
2001
301
0.040
Why?
Genomics
1
2019
123
0.040
Why?
Confidentiality
1
1998
10
0.040
Why?
Atypical Squamous Cells of the Cervix
1
2017
2
0.040
Why?
Phylogeny
1
2020
479
0.040
Why?
Proportional Hazards Models
2
2010
226
0.040
Why?
Tumor Virus Infections
1
1997
14
0.030
Why?
Societies, Medical
1
2017
93
0.030
Why?
Probability
2
2010
78
0.030
Why?
Weight Gain
1
1998
75
0.030
Why?
Endometrium
1
1997
39
0.030
Why?
Estrogen Replacement Therapy
1
1997
42
0.030
Why?
Human Papillomavirus DNA Tests
1
2016
2
0.030
Why?
Child
2
2010
2242
0.030
Why?
Transcription Factors
1
1999
520
0.030
Why?
Lung Neoplasms
1
1999
356
0.030
Why?
Condoms
1
1995
17
0.030
Why?
Menstrual Cycle
1
1995
24
0.030
Why?
Bacterial Proteins
1
2019
485
0.030
Why?
Psychosexual Development
1
1994
2
0.030
Why?
Adolescent Behavior
1
1995
68
0.030
Why?
Host-Pathogen Interactions
1
2014
91
0.030
Why?
Immunophenotyping
1
2014
60
0.030
Why?
DNA Helicases
1
2014
52
0.030
Why?
Chromosomes, Human, Pair 7
1
2013
12
0.030
Why?
Chromosomes, Human, Pair 20
1
2013
5
0.030
Why?
Chromosomes, Human, Pair 5
1
2013
10
0.030
Why?
Chromosomes, Human, Pair 3
1
2013
17
0.030
Why?
Models, Biological
2
2009
466
0.030
Why?
In Situ Hybridization, Fluorescence
1
2013
75
0.030
Why?
Glial Cell Line-Derived Neurotrophic Factor
1
2013
3
0.030
Why?
Area Under Curve
1
2013
95
0.030
Why?
Ablation Techniques
1
2013
12
0.030
Why?
DNA, Neoplasm
1
2013
34
0.030
Why?
Lymphoscintigraphy
1
2012
2
0.030
Why?
Oligonucleotides
1
2013
27
0.030
Why?
Health Care Costs
1
2013
50
0.030
Why?
Gene Expression Regulation, Neoplastic
2
2009
465
0.030
Why?
Groin
1
2012
3
0.020
Why?
Myometrium
1
2012
7
0.020
Why?
Parity
1
2012
49
0.020
Why?
Brachytherapy
2
2003
51
0.020
Why?
Laser Capture Microdissection
1
2012
9
0.020
Why?
Angiogenesis Inhibitors
1
2013
109
0.020
Why?
Cell Transformation, Neoplastic
1
2012
120
0.020
Why?
Vascular Endothelial Growth Factor A
1
2013
179
0.020
Why?
Polymerase Chain Reaction
1
2012
269
0.020
Why?
Postoperative Complications
2
2008
611
0.020
Why?
Ultrasonography
1
2012
241
0.020
Why?
Drug Implants
1
2010
14
0.020
Why?
Biopsy, Needle
1
2010
48
0.020
Why?
Parathyroid Hormone
1
2010
24
0.020
Why?
Drug Screening Assays, Antitumor
2
2001
103
0.020
Why?
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
2010
1
0.020
Why?
Vaccines, Virosome
1
2010
1
0.020
Why?
Severity of Illness Index
1
2012
452
0.020
Why?
Chi-Square Distribution
1
2010
145
0.020
Why?
Prenatal Care
1
2010
41
0.020
Why?
Vitamin D
1
2010
50
0.020
Why?
Product Surveillance, Postmarketing
1
2010
13
0.020
Why?
Academic Medical Centers
1
2010
75
0.020
Why?
Affect
1
2010
85
0.020
Why?
Receptor, ErbB-3
1
2009
1
0.020
Why?
Fever
1
2010
31
0.020
Why?
Headache
1
2010
34
0.020
Why?
Psychiatric Status Rating Scales
1
2010
98
0.020
Why?
Frozen Sections
1
2009
4
0.020
Why?
Tumor Cells, Cultured
2
2001
315
0.020
Why?
Gestational Age
1
2010
146
0.020
Why?
Receptor, ErbB-2
1
2009
33
0.020
Why?
Multivariate Analysis
1
2010
302
0.020
Why?
Karnofsky Performance Status
1
2009
15
0.020
Why?
Deoxycytidine
1
2009
65
0.020
Why?
Recurrence
1
2010
322
0.020
Why?
Genes, Viral
1
2009
10
0.020
Why?
Creatinine
1
2009
59
0.020
Why?
Drug-Related Side Effects and Adverse Reactions
1
2010
67
0.020
Why?
Risk
1
2009
137
0.020
Why?
Smoking
1
2012
473
0.020
Why?
Women
1
2008
12
0.020
Why?
Automation
1
2008
19
0.020
Why?
Sutures
1
2008
15
0.020
Why?
Weight Loss
1
2009
81
0.020
Why?
Medical Records
1
2008
51
0.020
Why?
Infusions, Parenteral
1
2007
37
0.020
Why?
Antibodies, Monoclonal
1
2009
330
0.020
Why?
Magnetic Resonance Imaging
1
2012
819
0.020
Why?
RNA, Messenger
1
2009
659
0.020
Why?
Patient Compliance
1
2007
75
0.020
Why?
Pain
1
2010
258
0.020
Why?
Software
1
2008
125
0.020
Why?
Quality of Life
1
2010
487
0.020
Why?
Ifosfamide
1
2005
9
0.020
Why?
Body Mass Index
1
2007
399
0.020
Why?
Doxorubicin
1
2005
77
0.010
Why?
Artifacts
1
2005
50
0.010
Why?
Lymphatic System
1
2004
11
0.010
Why?
Oligonucleotide Array Sequence Analysis
1
2005
194
0.010
Why?
Psychopathology
1
1964
6
0.010
Why?
Social Conditions
1
1964
5
0.010
Why?
Breast Diseases
1
1964
7
0.010
Why?
Classification
1
1964
15
0.010
Why?
Fiber Optic Technology
1
2004
14
0.010
Why?
Injections, Intramuscular
1
2004
22
0.010
Why?
Drug Combinations
1
2004
50
0.010
Why?
Subclavian Vein
1
2003
4
0.010
Why?
Fear
1
1964
60
0.010
Why?
Equipment Failure
1
2003
31
0.010
Why?
Physical Examination
1
1964
53
0.010
Why?
Reference Values
1
2004
199
0.010
Why?
Viral Proteins
1
2004
63
0.010
Why?
Health Education
1
1964
71
0.010
Why?
Virion
1
2003
6
0.010
Why?
Capsules
1
2003
8
0.010
Why?
Plasminogen
1
2003
8
0.010
Why?
Palliative Care
1
1964
82
0.010
Why?
Papillomavirus E7 Proteins
1
2003
8
0.010
Why?
Physician-Patient Relations
1
1964
115
0.010
Why?
Particle Size
1
2003
101
0.010
Why?
Anxiety
1
1964
149
0.010
Why?
Plasmids
1
2003
126
0.010
Why?
Antibody Specificity
1
2003
114
0.010
Why?
Antibodies, Viral
1
2003
79
0.010
Why?
Metabolic Clearance Rate
1
2002
18
0.010
Why?
Intestinal Obstruction
1
2002
9
0.010
Why?
Radionuclide Imaging
1
2002
56
0.010
Why?
Radiation Protection
1
2002
17
0.010
Why?
Aorta, Abdominal
1
2002
15
0.010
Why?
Hysterectomy, Vaginal
1
2001
4
0.010
Why?
Meta-Analysis as Topic
1
2001
32
0.010
Why?
Fenretinide
1
2001
4
0.010
Why?
T-Lymphocytes
1
2003
282
0.010
Why?
In Situ Nick-End Labeling
1
2001
43
0.010
Why?
Statistics, Nonparametric
1
2001
82
0.010
Why?
Myocardium
1
2002
192
0.010
Why?
Aorta, Thoracic
1
2001
55
0.010
Why?
Mucin-1
1
2001
36
0.010
Why?
Analysis of Variance
1
2001
391
0.010
Why?
Feasibility Studies
1
2001
193
0.010
Why?
Length of Stay
1
2001
229
0.010
Why?
Retinoic Acid Receptor alpha
1
1999
5
0.010
Why?
Retinoid X Receptors
1
1999
24
0.010
Why?
Transcription Factor AP-1
1
1999
26
0.010
Why?
Neoplasm Transplantation
1
1999
90
0.010
Why?
Cell Division
1
1999
154
0.010
Why?
DNA-Binding Proteins
1
2003
490
0.010
Why?
Structure-Activity Relationship
1
1999
208
0.010
Why?
Phenotype
1
2001
681
0.010
Why?
Mice, Nude
1
1999
331
0.010
Why?
Breast Neoplasms
1
1964
459
0.010
Why?
Transcription, Genetic
1
1999
403
0.010
Why?
Metaplasia
1
1997
5
0.010
Why?
In Situ Hybridization
1
1997
34
0.010
Why?
Epithelium
1
1997
39
0.010
Why?
Apoptosis
1
2001
775
0.010
Why?
Neoplasms
1
1964
809
0.010
Why?
Mice
1
1999
4654
0.010
Why?
Animals
1
1999
10423
0.000
Why?
Gold's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (433)
Explore
_
Co-Authors (12)
Explore
_
Similar People (59)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_